Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0.00 | $0.00 | $50.7M | $291M | $389M |
| Revenue growth | — | — | — | — | — | — | — | — | 473.0% | 33.9% |
| Operating income | -$1.14M | -$4.77M | -$11.9M | -$22.1M | -$33.0M | -$68.3M | -$145M | -$110M | $65.7M | $161M |
| Operating margin | — | — | — | — | — | — | — | -216.2% | 22.6% | 41.5% |
| Net income | -$1.15M | -$7.92M | -$10.9M | -$19.1M | -$32.2M | -$69.6M | -$140M | $10.9M | $89.2M | $205M |
| Net margin | — | — | — | — | — | — | — | 21.6% | 30.7% | 52.6% |
| EPS (diluted) | -$1.31 | -$1.48 | -$0.97 | -$1.20 | -$1.71 | -$3.13 | -$5.49 | $0.39 | $3.00 | $6.84 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.31M | -$3.89M | -$9.45M | -$18.7M | -$26.1M | -$47.9M | -$101M | -$88.8M | $123M | $201M |
| Capital expenditures | $15.0K | $210K | $2.23M | $6.40M | $14.8M | $68.3M | $53.0M | $11.8M | $4.24M | $12.0M |
| Free cash flow | -$1.33M | -$4.10M | -$11.7M | -$25.1M | -$40.9M | -$116M | -$154M | -$101M | $119M | $189M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.92M | $49.6M | $104M | $188M | $268M | $341M | $162M | $358M | $345M | $496M |
| Total assets | $2.18M | $50.1M | $116M | $209M | $311M | $626M | $558M | $818M | $1.06B | $1.33B |
| Total liabilities | $1.89M | $640K | $2.89M | $6.11M | $18.8M | $32.7M | $36.2M | $39.7M | $109M | $114M |
| Long-term debt | — | $4.25M | — | — | — | — | — | — | — | — |
| Shareholders' equity | $289K | $49.5M | $113M | $203M | $292M | $594M | $522M | $779M | $946M | $1.22B |
| Retained earnings | -$1.15M | -$9.07M | -$20.0M | -$39.0M | -$71.2M | -$141M | -$281M | -$270M | -$181M | $24.2M |
| Shares (wtd avg diluted) | — | 3.49M | 14.4M | 17.4M | 18.8M | 22.2M | 25.5M | 27.8M | 29.7M | 30.0M |
Every figure is extracted from Krystal Biotech, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.